The planned trial targets adults with Stage 2-4 chronic kidney disease and will track kidney function and inflammation markers. Recruitment starts after listing. Post Views: 0
Gummy dietary supplement provider TopGum has completed its acquisition of pharmaceuticals company P&L Developments’ (PLD) gummy manufacturing operations for US$35 million. The transaction was first announced in January this year and extends TopGum’s